CY 09 is a novel, potent, selective and direct NLRP3 inhibitor that blocks NLRP3 inflammasome assembly and activation, and exhibits therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes. It binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation.

纯度：≥98%

CAS：1073612-91-5